Brain-neuron targeted nanoparticles for peptide synergy therapy at dual-target of Alzheimer’s disease

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · see citing works

Drug combination studies and their synergy quantification using the Chou-Talalay method

Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · see citing works

Alzheimer's disease

Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32205-4 · Cited by 5,465 · see citing works

Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles

Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126 · see citing works

Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?

Leng, F., & Edison, P. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00435-y · Cited by 3,179 · see citing works

Microglia in Alzheimer’s disease

Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935 · see citing works

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy

Pérez‐Herrero, E., & Fernández‐Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,888 · see citing works

High-Level Neuronal Expression of Aβ_1–42in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation

Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · see citing works

Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models

Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821 · see citing works

Alzheimer Mechanisms and Therapeutic Strategies

Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · see citing works

Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease

Ittner, L. M., & Götz, J. (2010) · Nature reviews. Neuroscience · doi:10.1038/nrn2967 · Cited by 1,357 · see citing works

Tau-targeting therapies for Alzheimer disease

Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · see citing works

Basics and Recent Advances in Peptide and Protein Drug Delivery

Bruno, B. J., Miller, G. D., & Lim, C. S. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.104 · Cited by 760 · see citing works

β-Amyloid Stimulation of Microglia and Monocytes Results in TNFα-Dependent Expression of Inducible Nitric Oxide Synthase and Neuronal Apoptosis

Combs, C. K., Karlo, J. C., Kao, S.-C., & Landreth, G. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-04-01179.2001 · Cited by 721 · see citing works

Alzheimer's disease drug development pipeline: 2018

Cummings, J., Lee, G., Ritter, A., & Zhong, K. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.03.009 · Cited by 697 · see citing works

Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer’s disease Neurons

Rajmohan, R., & Reddy, P. H. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160612 · Cited by 695 · see citing works

Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes

Nortley, R., Korte, N., Izquierdo, P., Hirunpattarasilp, C., Mishra, A., Jaunmuktane, Z., Kyrargyri, V., Pfeiffer, T., Khennouf, L., Madry, C., et al. (2019) · Science · doi:10.1126/science.aav9518 · Cited by 682 · see citing works

Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice

Rhein, V., Song, X., Wiesner, A., Ittner, L. M., Baysang, G., Meier, F., Ozmen, L., Bluethmann, H., Dröse, S., Brandt, U., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905529106 · Cited by 655 · see citing works

Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons

Um, J. W., Nygaard, H. B., Heiss, J. K., Kostylev, M. A., Stagi, M., Vortmeyer, A. O., Wısnıewskı, T., Gunther, E. C., & Strittmatter, S. M. (2012) · Nature Neuroscience · doi:10.1038/nn.3178 · Cited by 654 · see citing works

Amyloid-β plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation

He, Z., Guo, J. L., McBride, J. D., Narasimhan, S., Kim, H., Changolkar, L., Zhang, B., Gathagan, R. J., Yue, C., Dengler, C., et al. (2018) · Nature Medicine · doi:10.1038/nm.4443 · Cited by 645 · see citing works

p62 Is a Common Component of Cytoplasmic Inclusions in Protein Aggregation Diseases

Zatloukal, K., Stumptner, C., Fuchsbichler, A., Heid, H., Schnoelzer, M., Kenner, L., Kleinert, R., Prinz, M., Aguzzi, A., & Denk, H. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64369-6 · Cited by 624 · see citing works

Oligomeric Aβ-induced synaptic dysfunction in Alzheimer’s disease

Tu, S., Okamoto, S., Lipton, S. A., & Xu, H. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-48 · Cited by 582 · see citing works

Amyloid-β-independent regulators of tau pathology in Alzheimer disease

van der Kant, R., Goldstein, L. S. B., & Ossenkoppele, R. (2020) · Nature reviews. Neuroscience · doi:10.1038/s41583-019-0240-3 · Cited by 580 · see citing works

Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies

Dejanovic, B., Huntley, M. A., De Mazière, A., Meilandt, W. J., Wu, T., Srinivasan, K., Jiang, Z., Gandham, V., Friedman, B. A., Ngu, H., et al. (2018) · Neuron · doi:10.1016/j.neuron.2018.10.014 · Cited by 575 · see citing works

Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis

Small, S. A., & Duff, K. (2008) · Neuron · doi:10.1016/j.neuron.2008.11.007 · Cited by 546 · see citing works

Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis

Qiu, W. Q., & Folstein, M. F. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.01.004 · Cited by 538 · see citing works

Amyloid-β and tau complexity — towards improved biomarkers and targeted therapies

Polanco, J. C., Li, C., Bodea, L., Martínez‐Mármol, R., Meunier, F. A., & Götz, J. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.162 · Cited by 374 · see citing works

Nanoparticles for combination drug therapy

Ma, L., Kohli, M., & Smith, A. (2013) · ACS Nano · doi:10.1021/nn405674m · Cited by 367 · see citing works

Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies

Kuusisto, E., Salminen, A., & Alafuzoff, I. I. (2001) · Neuroreport · doi:10.1097/00001756-200107200-00009 · Cited by 347 · see citing works

Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade

Gulisano, W., Maugeri, D., Baltrons, M. A., Fà, M., Amato, A., Palmeri, A., D’Adamio, L., Grassi, C., Devanand, D. P., Honig, L. S., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179935 · Cited by 313 · see citing works

Preclinicalversusclinical drug combination studies

Chou, T. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802353591 · Cited by 303 · see citing works

Targeting the brain with PEG–PLGA nanoparticles modified with phage-displayed peptides

Li, J., Feng, L., Fan, L., Zha, Y., Guo, L., Zhang, Q., Chen, J., Pang, Z., Wang, Y., Jiang, X., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.031 · Cited by 295 · see citing works

Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer’s Disease

Chen, Q., Du, Y., Zhang, K., Liang, Z., Li, J., Yu, H., Ren, R., Feng, J., Jin, Z., Li, F., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b07625 · Cited by 280 · see citing works

Analysis of Drug Interactions

Bijnsdorp, I. V., Giovannetti, E., & Peters, G. J. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-080-5_34 · Cited by 255 · see citing works

Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease

Karthivashan, G., Ganesan, P., Park, S., Kim, J.-S., & Choi, D. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1428243 · Cited by 227 · see citing works

Combination Drug Therapy for the Management of Alzheimer’s Disease

Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217 · see citing works

Pathways by Which Aβ Facilitates Tau Pathology

Blurton-Jones, M. M., & LaFerla, F. M. (2006) · Current Alzheimer Research · doi:10.2174/156720506779025242 · Cited by 195 · see citing works

Rethinking CRITID Procedure of Brain Targeting Drug Delivery: Circulation, Blood Brain Barrier Recognition, Intracellular Transport, Diseased Cell Targeting, Internalization, and Drug Release

Ruan, S., Zhou, Y., Jiang, X., & Gao, H. (2021) · Advanced Science · doi:10.1002/advs.202004025 · Cited by 195 · see citing works

Intranasal H102 Peptide-Loaded Liposomes for Brain Delivery to Treat Alzheimer’s Disease

Zheng, X., Shao, X., Zhang, C., Tan, Y., Liu, Q., Xu, W., Zhang, Q., Xu, S., & Jiang, X. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1744-9 · Cited by 193 · see citing works

Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer’s disease

Krause, D. L., & Müller, N. (2010) · International Journal of Alzheimer's Disease · doi:10.4061/2010/732806 · Cited by 168 · see citing works

Targeting Fyn Kinase in Alzheimer’s Disease

Nygaard, H. B. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.06.004 · Cited by 162 · see citing works

Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer's disease

Wang, P., Zheng, X., Guo, Q., Yang, P., Pang, X., Qian, K., Lü, W., Zhang, Q., & Jiang, X. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.034 · Cited by 162 · see citing works

Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage

Matsuoka, Y., Gray, A. J., Hirata‐Fukae, C., Minami, S., Waterhouse, E. G., Mattson, M. P., LaFerla, F. M., Gozes, I., & Aisen, P. S. S. (2007) · Journal of Molecular Neuroscience · doi:10.1385/jmn/31:02:165 · Cited by 161 · see citing works

Amyloid-β42/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer’s disease

Kwak, S. S., Washicosky, K. J., Brand, E., von Maydell, D., Aronson, J., Kim, S., Capen, D. E., Cetinbas, M., Sadreyev, R., Ning, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15120-3 · Cited by 151 · see citing works

NAP: Research and Development of a Peptide Derived from Activity-Dependent Neuroprotective Protein (ADNP)

Gozes, I., Morimoto, B. H., Tiong, J., Fox, A. W., Sutherland, K., Dangoor, D., Holser-Cochav, M., Vered, K., Newton, P. E., Aisen, P. S. S., et al. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2005.tb00053.x · Cited by 144 · see citing works

Smart Targeting To Improve Cancer Therapeutics

Morales‐Cruz, M., Delgado, Y., Castillo, B., Figueroa, C. M., Molina, A., Torres, A., Milián, M., & Griebenow, K. H. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s219489 · Cited by 144 · see citing works

Neuronal mitochondria-targeted micelles relieving oxidative stress for delayed progression of Alzheimer's disease

Yang, P., Sheng, D., Guo, Q., Wang, P., Xu, S., Qian, K., Li, Y., Cheng, Y., Wang, L., Lü, W., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119844 · Cited by 139 · see citing works

Alzheimer's disease failed clinical trials

Asher, S., & Priefer, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120861 · Cited by 124 · see citing works

NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model

Shiryaev, N., Jouroukhin, Y., Giladi, E., Polyzoidou, E., Grigoriadis, N., Rosenmann, H., & Gozes, I. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.011 · Cited by 122 · see citing works

A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting

Liu, J. K., Teng, Q., Garrity‐Moses, M. E., Federici, T., Tănase, D., Imperiale, M. J., & Boulis, N. M. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.01.022 · Cited by 119 · see citing works

Combination Therapy of Experimental Candidiasis, Cryptococcosis, Aspergillosis and Wangiellosis in Mice

Polak, A. (2009) · Chemotherapy · doi:10.1159/000238524 · Cited by 116 · see citing works

Peptide‐Mediated Blood–Brain Barrier Transport of Polymersomes

Georgieva, J. V., Brinkhuis, R. P., Stojanov, K., Weijers, C. A. G. M., Zuilhof, H. T., Rutjes, F. P. J. T., Hoekstra, D., van Hest, J. C. M., & Zuhorn, I. S. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201202001 · Cited by 113 · see citing works

A dual-ligand fusion peptide improves the brain-neuron targeting of nanocarriers in Alzheimer's disease mice

Guo, Q., Xu, S., Yang, P., Wang, P., Lü, S., Sheng, D., Qian, K., Cao, J., Lü, W., & Zhang, Q. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.039 · Cited by 103 · see citing works

Cognitive impact of neuronal pathology in the entorhinal cortex and CA1 field in Alzheimer's disease

GUNTEN, A., KOVARI, E., BUSSIERE, T., RIVARA, C., GOLD, G., BOURAS, C., HOF, P., & GIANNAKOPOULOS, P. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.02.008 · Cited by 101 · see citing works

The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer's disease

Zhang, C., Zheng, X., Xu, W., Shao, X., Liu, Q., Zhang, Z., & Zhang, Q. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.050 · Cited by 100 · see citing works

Pathways linking Aβ and tau pathologies

LaFerla, F. M. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380993 · Cited by 83 · see citing works

A hybrid siRNA delivery complex for enhanced brain penetration and precise amyloid plaque targeting in Alzheimer’s disease mice

Zheng, X., Pang, X., Yang, P., Xu, W., Wei, Y., Guo, Q., Zhang, Q., & Jiang, X. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.11.029 · Cited by 68 · see citing works

An evaluation of memantine ER + donepezil for the treatment of Alzheimer’s disease

Calhoun, A. J., King, C., Khoury, R., & Grossberg, G. T. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1519022 · Cited by 61 · see citing works

Combination of Farnesyltransferase and Akt Inhibitors Is Synergistic in Breast Cancer Cells and Causes Significant Breast Tumor Regression in ErbB2 Transgenic Mice

Balasis, M. E., Forinash, K. D., Chen, Y. A., Fulp, W. J., Coppola, D., Hamilton, A. D., Cheng, J. Q., & Sebti, S. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2544 · Cited by 60 · see citing works

Brain Delivery of NAP with PEG-PLGA Nanoparticles Modified with Phage Display Peptides

Li, J., Zhang, C., Li, J., Li, F., Jiang, X., Chen, J., Pang, Z., & Zhang, Q. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1025-4 · Cited by 57 · see citing works

Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer's disease

Mori, T., Koyama, N., Tan, J., Segawa, T., Maeda, M., & Town, T. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.762658 · Cited by 57 · see citing works

Advancing combination therapy for Alzheimer's disease

Salloway, S., Sevingy, J., Budur, K., Pederson, J., DeMattos, R., von Rosenstiel, P., Páez, A., Evans, R., Weber, C. J., Hendrix, J. A., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/trc2.12073 · Cited by 57 · see citing works

The Binding Receptors of Aβ: an Alternative Therapeutic Target for Alzheimer’s Disease

Xia, M., Cheng, X., Yi, R., Gao, D., & Xiong, J. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8994-0 · Cited by 53 · see citing works

Down‐regulation of glutamatergic terminals (VGLUT1) driven by Aβ in Alzheimer's disease

Rodriguez‐Perdigon, M., Tordera, R. M., Gil-Bea, F. J., Gereñu, G., Ramírez, M. J., & Solas, M. (2016) · Hippocampus · doi:10.1002/hipo.22607 · Cited by 47 · see citing works

Modulating autophagic flux via ROS-responsive targeted micelles to restore neuronal proteostasis in Alzheimer's disease

Xu, S., Yang, P., Qian, K., Li, Y., Guo, Q., Wang, P., Meng, R., Wu, J., Cao, J., Cheng, Y., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.09.017 · Cited by 47 · see citing works

Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease

Timmers, M., Tesseur, I. C., Bogert, J., Zetterberg, H., Blennow, K., Börjesson‐Hanson, A., Baquero, M., Boada, M., RANDOLPH, C. C., Tritsmans, L., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.03.016 · Cited by 42 · see citing works

Combination of arsenic trioxide and chemotherapy in small cell lung cancer

Zheng, C., Lam, S. K., Li, Y., Fong, B. M.-W., Mak, J., & Ho, J. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.08.022 · Cited by 38 · see citing works

Optimization of Tet1 ligand density in HPMA-co-oligolysine copolymers for targeted neuronal gene delivery

Chu, D. S. H., Schellinger, J. G., Bocek, M. J., Johnson, R. N., & Pun, S. H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.08.045 · Cited by 35 · see citing works

Combination therapy for Alzheimer's disease and related dementias

Bednar, M. M. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.10.001 · Cited by 9 · see citing works

Precision drug delivery to the central nervous system using engineered nanoparticles

Gao, J., Xia, Z. J., Gunasekar, S., Jiang, C., Karp, J. M., & Joshi, N. (2024) · Nature Reviews Materials · doi:10.1038/s41578-024-00695-w · Cited by 162 · see citing works

Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease

Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56 · see citing works

Emerging nanotechnology for Alzheimer's disease: From detection to treatment

Song, N., Sun, S., Chen, K., Wang, Y., Wang, H., Meng, J., Guo, M., Zhang, X.-D., & Zhang, R. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.004 · Cited by 44 · see citing works

Revolutionizing Alzheimer's treatment: Harnessing human serum albumin for targeted drug delivery and therapy advancements

Shastri, D., Raj, V., & Lee, S.-K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102379 · Cited by 34 · see citing works

Clinical translation of nanomedicines for brain diseases: Current challenges and future directions

Wang, G., Wang, N., Xia, X., Ismail, M., & Shi, B. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114426 · Cited by 33 · see citing works

Framework Nucleic Acid Nanomaterials for Central Nervous System Therapies: Design for Barrier Penetration, Targeted Delivery, Cellular Uptake, and Endosomal Escape

Chen, X., Luo, X., Yin, W., Cui, W., He, Y., Tian, T., & Lin, Y. (2025) · ACS Nano · doi:10.1021/acsnano.5c03945 · Cited by 36 · see citing works

Precise Modulation of Pericyte Dysfunction by a Multifunctional Nanoprodrug to Ameliorate Alzheimer’s Disease

Yang, P., Li, Y., Qian, K., Zhou, L., Cheng, Y., Wu, J., Xu, M., Wang, T., Yang, X., Mu, Y., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c00480 · Cited by 30 · see citing works

Multidimensional autophagy nano-regulator boosts Alzheimer's disease treatment by improving both extra/intraneuronal homeostasis

Li, Y., Yang, P., Meng, R., Xu, S., Zhou, L., Qian, K., Wang, P., Cheng, Y., Sheng, D., Xu, M., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.10.009 · Cited by 26 · see citing works

Neuronanomedicine for Alzheimer’s and Parkinson’s disease: Current progress and a guide to improve clinical translation

Boyton, I., Valenzuela, S. M., Collins‐Praino, L. E., & Care, A. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.11.004 · Cited by 23 · see citing works

Advanced nanoparticle engineering for precision therapeutics of brain diseases

Ismail, M., Liu, J., Wang, N., Zhang, D., Qin, C., Shi, B., & Zheng, M. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123138 · Cited by 23 · see citing works

The Application of Polymeric Nanoparticles as Drug Delivery Carriers to Cells in Neurodegenerative Diseases

Jin, L. J., Nie, L., Deng, Y., Khana, G. J., & He, N. (2025) · Cell Proliferation · doi:10.1111/cpr.13804 · Cited by 24 · see citing works

ROS Regulation in CNS Disorder Therapy: Unveiling the Dual Roles of Nanomedicine

Quan, Z., Wang, S., Xie, H., Zhang, J., Duan, R., Li, M., & Zhang, J. (2024) · Small · doi:10.1002/smll.202410031 · Cited by 18 · see citing works

Nanomedicine for targeting brain Neurodegeneration: Critical barriers and circadian rhythm Considerations

Pineiro‐Alonso, L., Rubio-Prego, I., Lobyntseva, A., González‐Freire, E., Langer, R., & Alonso, M. J. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115606 · Cited by 18 · see citing works

Peptide-based inhibitors and nanoparticles: Emerging therapeutics for Alzheimer’s disease

Mojarad-Jabali, S., & Roh, K. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125055 · Cited by 17 · see citing works

Cytoskeleton-modulating nanomaterials and their therapeutic potentials

Park, J.-W., Wu, Y., Kim, J. S., Byun, J., Lee, J., & Oh, Y. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115362 · Cited by 16 · see citing works

Harnessing nanomedicine for modulating microglial states in the central nervous system disorders: Challenges and opportunities

Li, H., Guan, M., Zhang, N.-N., Wang, Y., Liang, T., Wu, H., Wang, C., Sun, T., & Liu, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117011 · Cited by 16 · see citing works

Redox Oxygen Species‐Responsive Nanotheranostics with Dual‐Channel Fluorescent Turn‐On for Early Diagnosis and Targeted Therapy of Alzheimer's Disease

Guo, Q., Wang, T., Qian, C., & Wang, X. (2024) · Small · doi:10.1002/smll.202403980 · Cited by 15 · see citing works

Borneol and lactoferrin dual-modified crocetin-loaded nanoliposomes enhance neuroprotection in HT22 cells and brain targeting in mice

Tong, Z., Jie, X., Chen, Z., Deng, M., Li, X., Zhang, Z., Pu, F., Xie, Z., Xu, Z., & Wang, P. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116674 · Cited by 12 · see citing works

Improving mitochondrial function for alleviating memory decline of aging mice via dual-delivering lycopene nanoparticles

Xia, X., Li, H., Xu, X., Wang, Z., Zhao, G., & Du, M. (2024) · Applied Materials Today · doi:10.1016/j.apmt.2024.102132 · Cited by 11 · see citing works

Promising Natural Remedies for Alzheimer’s Disease Therapy

Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2025) · Molecules · doi:10.3390/molecules30040922 · Cited by 13 · see citing works

Functional nanomaterial strategies for targeted CNS drug delivery

Ye, R., Zhang, Y., Jiao, X., Xu, W. X., Chen, Y., Nai, L., Guo, Q., Wang, J., Zhao, Z., Liu, S., et al. (2025) · Nano Research · doi:10.26599/nr.2025.94907836 · Cited by 9 · see citing works

Engineering small extracellular vesicles with multivalent DNA probes for precise tumor targeting and enhanced synergistic therapy

Zhang, Q., Ma, R., Ren, T.-J., Ren, X.-Y., & Xu, Z. (2024) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2024.09.224 · Cited by 7 · see citing works

Directional conjugation of monoclonal antibodies to nanoparticles using metal-free click chemistry

Jeevarathinam, A. S., Kawelah, M. R., Han, S., Grindel, B. J., Millward, S. W., Johnston, K. P., & Sokolov, K. (2025) · Nature Protocols · doi:10.1038/s41596-025-01272-3 · Cited by 4 · see citing works

Bionanoconjugates in Neurodegeneration: Peptide–Nanoparticle Alliances for Next-Generation Therapies

Ranjitha, V. R., Kumar, P. S. A., & Kaalappa, P. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03941-0 · Cited by 3 · see citing works

A Chemically Engineered Macrocyclic Peptide Shuttle Overcomes Blood‐Brain Barrier in Aging Brain

Peng, L., Li, Q., Li, Z., Tian, Y., & Zhou, S. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202520279 · Cited by 3 · see citing works

Nanomedicine in Alzheimer’s Therapy: Enhancing Drug Delivery Strategies

Singh, A., Mazumder, A., Das, S., Mishra, R., & Chaitanya, M. (2024) · Current Nanomedicine · doi:10.2174/0124681873312057240622175745 · Cited by 3 · see citing works

Nanomaterials for Alzheimer’s disease: emerging strategies in diagnosis and therapy

Na, Y., Bai, J., Zhang, N., Geng, F., & Wang, X.-J. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04281-w · Cited by 2 · see citing works

Innovative dual-target AKT inhibitors unveiling novel mechanisms and translational potential

Yan, S. Z., Wang, L., Liu, D., Qin, H., Du, C., Chai, J., Liu, Y., Chen, Y., Liu, H., & Jin, T. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108774 · Cited by 2 · see citing works

Multidisciplinary examples of applications: Papers using the MAL-PD/BD/CI/BI theory/method

Chou, T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28874-6.00010-x · Cited by 1 · see citing works

Alzheimer’s Disease, Epilepsy, and Vascular Dementia: Convergent Mechanisms and Shared Therapeutic Pathways

Omar, S. H., & Ghani, M. A. (2025) · Journal of Vascular Diseases · doi:10.3390/jvd4040044 · Cited by 1 · see citing works

A Chemically Engineered Macrocyclic Peptide Shuttle Overcomes Blood‐Brain Barrier in Aging Brain

Peng, L., Li, Q., Li, Z., Tian, Y., & Zhou, S. (2025) · Angewandte Chemie · doi:10.1002/ange.202520279 · Cited by 1 · see citing works

Analysis of the dual role of amyloid-beta in Alzheimer’s disease through multi-omics integration

Guo, J., Lu, X., Qiu, L., Xue, W., Fu, H., Wang, K., & Wang, Y. (2026) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00872 · Cited by 1 · see citing works

Synergistic thrombin inhibition by Diospyros lotus pomace peptides and gallic acid: an in vitro assessment of effects and mechanisms

Shi, Z.-W., Cai, H., Ren, H., Shang, X.-N., An, S.-Y., & Ren, D. (2025) · Journal of Food Measurement & Characterization · doi:10.1007/s11694-025-03874-7

Transforming anti-Alzheimer’s therapy by targeting endogenous receptorrial system through ligand-conjugated nanoformulations

Gawai, M., Nistane, N. T., Tatode, A., Qutub, M., Umekar, M. J., Premchandani, T., & Taksande, J. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102994

Synergistic Effects of Sinomenine Hydrochloride and Low-Dose Donepezil on Cognitive Decline: Combined Modulation of Cholinergic Function and Nrf2-Mediated Antioxidant Response

Rotu, R. A., Oyovwi, M. O., Dele-Ochie, P. E., Rotu, R. A., Ibekwe, A. M., Ben-Azu, B., & Ayegboyin, O. A. (2026) · Trends in Biological Sciences · doi:10.21124/tbs.2026.15.23

Nanotechnology-mediated drug delivery for addressing protein aggregation

Tripathi, S., Jaiswal, S., Rana, R., Yadav, P., Mishra, K., Sethi, M., & Chourasia, M. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33623-2.00004-0

Multi-functional bionic nanoparticles for precise neuronal targeting and synergistic therapy in Alzheimer's disease

Na, Y., Liu, C., Bi, X., Liu, S., Xing, Y., Zhang, B.-H., Liu, T.-F., Zhang, N., & Geng, F. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103617

Fabrication of Mesoporous Manganese Nanoparticles Incorporated Aβ‐Peptide Inhibits Aβ Aggregation and Alleviates Neuroinflammation Against Alzheimer's Disease

Lu, H., Hu, C., & Fu, Y. (2026) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.70131

Developing precision nanoparticle-based drug delivery systems for Alzheimer's disease therapy

Shan, Q., Zheng, W., Yao, W., Bai, Y., Ding, W., Wang, J., & Bai, F. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103789

Icariin, a Multi-Target Natural Neuroprotectant, and a Comprehensive Review on Its Synthetic Methods, Pharmacological Evaluation and Pharmacokinetic Characteristics

Zhang, K., Li, J., Ban, W., Chen, P., Ding, X., Lv, L., Guo, B., & Yang, Z. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219562

Multi-functional bionic nanoparticles for precise neuronal targeting and synergistic therapy in Alzheimer's disease

Na, Y., Liu, C., Bi, X., Liu, S., Xing, Y., Zhang, B.-H., Liu, T.-F., Zhang, N., & Geng, F. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103617

A Novel Targeted and High‐Efficiency Nanosystem for Combinational Therapy for Alzheimer's Disease

Yang, H. N., Mu, W., Wei, D., Zhang, Y., Duan, Y., Gao, J., Gong, X., Wang, H., Wu, X., Tao, H., et al. (2020) · Advanced Science · doi:10.1002/advs.201902906 · Cited by 78 · see citing works

Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease

Mashal, Y., Abdelhady, H. G., & Iyer, A. K. (2022) · Biomolecules · doi:10.3390/biom12071001 · Cited by 20 · see citing works

A dual-ligand fusion peptide improves the brain-neuron targeting of nanocarriers in Alzheimer's disease mice

Guo, Q., Xu, S., Yang, P., Wang, P., Lü, S., Sheng, D., Qian, K., Cao, J., Lü, W., & Zhang, Q. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.039 · Cited by 103 · see citing works

“Drug‐Carrier” Synergy Therapy for Amyloid‐<i>β</i> Clearance and Inhibition of Tau Phosphorylation via Biomimetic Lipid Nanocomposite Assembly

Han, G., Bai, K., Yang, X., Sun, C., Ji, Y., Zhou, J., Zhang, H., & Ding, Y. (2022) · Advanced Science · doi:10.1002/advs.202106072 · Cited by 46 · see citing works